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Summary Progress in our understanding of the contribution of P-glycoprotein (P-gp)-mediated resistance to chemotherapy failure in
haematological as well as solid tumours has been hampered by the lack of highly sensitive, reliable methods forthe detection of P-gp function
in fresh human tumour cells. The present study identifies the novel nucleic acid stain SYT016 as a highly sensitive and specific dye to assess
P-gp function. The effect of P-gp is expressed here as the ratio of dye fluorescence (RF) from cells incubated with dye with or without 2 gM of
the P-gp inhibitor PSC 833. Using flow cytometric analysis, an RF of 0.9 was found for SYT016 in the KB3-1 (P-gp-) and 1.6 in KB8 (P-gp+)
cells. Three types of patients' cells were studied: (1) in haematopoietic CD34+ cells, which are known to express P-gp, the RF was 6.0 for
SYTO16 compared with 2.5 for rhodamine 123 and 1.3 for daunorubicin (mean of five individuals); (2) in acute myeloid leukaemia cells, the
RF for SYTO16 was 1.0 in P-gp- and 4.5 in P-gp+ samples; (3) for the first time, we have quantitated P-gp function in fresh human solid
tumour (sarcoma) cells. We found, in a P-gp+ leiomyosarcoma, an RF of 16 for SYT016 and 2.7 for daunorubicin. This means that complete
inhibition of P-gp function in these sarcoma cells would lead to an increase of daunorubicin accumulation with 170% compared with 30% in
the CD34+ cells. Next, we showed that SYTO16 could be fixed in nuclei by 3.6% formaldehyde treatment, allowing quantification of the
nuclear fluorescence on cytospins by laser scanning microscopy. In conclusion, SYTO16 proved to have a combination of favourable
properties: it can be excited at 488 nm and has large fluorescence enhancement upon binding to nucleic acids, allowing the use of low, non-
toxic (< 10 nM) concentrations. Because the RF for SYT016 is much higher than for daunorubicin, it can be applied for the determination of
P-gp function in relatively small numbers of low-P-gp-expressing tumour cells by laser scanning microscopy. Individual sarcomas were found
to have high P-gp function compared with CD34+ cells. This assay may be used to select patients for P-gp modulation protocols.
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The putative role ofP-glycoprotein (P-gp) in chemotherapy resis-
tance of human cancer has been studied extensively since P-gp
was discovered (Juliano and Ling, 1976). In particular, the avail-
ability of monoclonal antibodies (Kartner et al, 1985; Scheper et
al, 1988) and gene probes (Noonan et al, 1990) has greatly stimu-
lated studies that have addressed the expression ofP-gp in human
tumour cells. Most ofthese studies correlate P-gp expression with
clinical parameters, such as response to chemotherapy, duration of
response or survival. Such studies are important because they may
provide a rationale to adapt the treatment of patients predicted to
have a poor response. In particular, the selection of patients for
clinical trials with chemotherapy regimens aimed to circumvent or
overcome the drug efflux by P-gp may be guided by measurements
ofP-gp levels in the patients' tumour cells. Progress in our under-
standing ofthe impact ofP-gp on the response ofcancerpatients to
chemotherapy is hampered by the inadequacy ofcurrent analytical
methods to determine tumour cell P-gp in a quantitative, sensitive
and reproducible way (Beck et al, 1996). A further improvement
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of immunocyto-/histochemical techniques to study low levels of
P-gp expression is necessary (Beck et al, 1996; Broxterman et al,
1996a). An alternative approach to study the impact of P-gp
expression is to measure the P-gp-mediated drug efflux in tumour
cells. Such functional P-gp assays have been extensively used to
assess drug transporter activity in cell lines and more recently in
normal haematopoietic cells (Neyfakh et al, 1989; Chaudhary and
Roninson, 1991) and haematological malignancies (Marie et al,
1993; Ross et al, 1993; Ino et al, 1994; Leith et al, 1995). These
assays are based on the ability of P-gp to export fluorescent dyes,
such as rhodamine 123, out of cells, allowing a convenient flow
cytometric determination of P-gp activity. Whereas these fluores-
cent dyes are used to detect the P-gp activity in leukaemic cells
(Broxterman et al, 1996 a and b), the specific problems with solid
tumours, such as the difficulty to obtain single-cell suspensions
leave this type ofassay still largely unexplored (Broxterman et al,
1990; Kunikane et al, 1995). The lack of P-gp functional assays
and of reliable immunohistochemical detection of P-gp has
precluded definitive conclusions on the role of P-gp in solid
tumours (Beck et al, 1996). Our purpose was to devise a sensitive
functional P-gp assay, applicable to the study of different types of
tumour cells. We describe the use of a novel nucleic acid stain
that appears to be a highly sensitive and specific probe for P-gp
function in haematological as well as solid tumour cells; as it can
be excited at 488 nm and fixed in the cells, quantitative analysis of
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Table 1 Comparison of P-gp probes for human CD34+ and tumour cells
SYTO13 SYTO16 SYTO16 Rho123 Daunorubicin DiOC2(3)
CLSM
KB3-1 1.01 ±0.19 0.90±0.14 1.08±0.12 0.98±0.06 1.10±0.06 1.05±0.09
KB8 1.79±0.15 1.61 ±0.26 1.98±0.40 1.59±0.20 1.17±0.11 1.50±0.16
KB8-5 29.7± 16.6 19.6±8.3 - 14.6-12.6 - -
GLC4 1.1-1.0 1.1-0.9 -
GLC4/ADR 0.9-0.9 0.8-0.9 -
HL60 0.9 ± 0.2 1.0 ± 0.3 -
HL60/ADR 1.2 ± 0.6 1.1 ± 0.3 - -
CD34+ - 6.0±2.2 4.0±2.4 2.5±0.5 1.3±0.1 -
AML1 (Pgp-) - 1.0 0.8 1.0 1.0 -
AML2 (Pgp-) 1.0 1.0 1.1 1.0 1.0 -
AML3 (Pgp+) - 3.2 4.8 1.6 1.2 -
AML4 (Pgp+) 2.9 3.7 4.5 2.8 1.2 -
Sarcoma 1 (Pgp+) - 16.0 10.7 4.9 2.7 -
Sarcoma 1 (40C, ON)a - 16.0 - 3.4 2.8 -
Sarcoma 1 (thawed) - 21.1 - 5.6 2.5 -
Sarcoma 2 (Pgp-) - 1.0 1.1 0.7 0.9 -
Sarcoma 3 (Pgp+) - 6.0c 3.9 2.5 1.5 -
Sarcoma 3 (RPMI)b - 15.6 - 3.0 1.9 -
Cells were loaded with dyes with or without 2gM PSC 833 for 75 min (daunorubicin, Rhol23 or DioC2 (3)) orfor 45 min with SYTO probes. For GLC4 and
GLC4/ADR, 1 mM probenecid was used as modulator (two experiments, separated by a hyphen). For HL60 and HL60/ADR, three different modulators were
used (1 mm probenecid, 200gM genistein and 2gM PSC 833; the results were averaged for this cell line). Fluorescence was measured on a FACS Calibur,
excitation at 488 nm, emission in FL1 or FL2 (daunorubicin) or by confocal laser scanning microscopy (CLSM). Data are ratios of mean fluorescence (RF) with
or without modulator. For KB3-1, KB8 and KB8-5, the data represent two experiments (separated by a hyphen) or means ± s.d. from three to five independent
experiments. For CD34+ cells, data are means ± s.d. from leucapheresis isolates of five different patients. For fresh tumour cells, data from individual samples
are shown. P-gp expression was measured in fresh tumour cells with MRK-16 as described (Broxterman et al, 1996b). The ratio of the MRK-16fisotype control
was 1.7 for both AMLs designated P-gp-, 7.9 and 9.0 for AMLs designated P-gp+ and 54, 1.6 and 12.7 (20.7 for cells in medium for 1 week) for the sarcoma
cells labelled 1, 2 and 3 respectively. aON, overnight. bRPMI, 1 week in medium. cFor 80% of the cells.
P-gp function at the single-cell level is possible using a confocal
laser scanning microscope (CLSM) equipped with an argon/
krypton (Ar/Kr) laser.
MATERIALS AND METHODS
Cell lines
The human epidermoid carcinoma cell line KB3-1 and its P-gp-
expressing sublines KB8 and KB8-5, which are about two and five
times, respectively, more resistant to daunorubicin (DNR)
than KB3-1, were cultured in Dulbecco's minimal essential
medium (DMEM; Flow Labs, Irvine, UK) with 7.5% fetal calf
serum (FCS; Gibco Europe, Paisley, UK). The GLC4 and HL60
and their multidrug resistance protein (MRP)-overexpressing
sublines GLC4/ADR and HL60/ADR cells were cultured in RPMI-
1640 + 10% FCS.
Patient material
Three types of cells were studied, namely human peripheral
CD34+cells, acute myeloid leukaemia (AML) and freshly dissoci-
ated sarcoma cells. Leucapheresis samples were obtained from
patients with haematological and oncological malignancies.
Patients were treated with granulocyte colony-stimulating factor
(G-CSF) and/or chemotherapy, resulting in increased numbers of
CD34+ cells in peripheral blood. These CD34+ cells were isolated
from leucapheresis samples after overmight storage at 4°C, using
the MiniMacs System (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer's instructions. The purity
was always > 90% CD34+, as determined by flow cytometric
analysis. Blood samples obtained from patients with AML were
subjected to Ficoll separation, and the nucleated cells were used
immediately for the P-gp assays or frozen in liquid nitrogen and
thawed as described (Broxterman et al, 1996b). Tumour tissue
(10-15 g) from two leiomyosarcomas (sarcoma 1 and 3, Table 1)
and one liposarcoma (sarcoma 2, Table 1) was dissociated
immediately after resection by collagenase-DNAase I treatment,
according to described methods (Broxterman et al, 1995). The
resulting cell suspensions were used forP-gp analysis immediately
after dissociation (3-4 h after tumour resection) or for comparison
after ovemight storage at 4°C (sarcoma 1), after freezing and
thawing (sarcoma 1) or after keeping cells for 1 week in RPMI
plus 20% FCS and glutamine at 37°C (sarcoma 3).
Clonogenic assay
The clonogenic capacity of the CD34+ cells was assayed in semi-
solid medium in the presence of5% placenta-conditioned medium
(3000-9000 cells per ml). Colonies (> 40 cells) and clusters (8-40
cells) were scored after 12 days. To study the toxicity ofSYTO16,
CD34+ cells were incubated for 45 min (the time chosen by us for
dye loading in P-gp activity assays) with increasing concentrations
of the dye and were washed and plated for 12 days in the clono-
genic assay.
Dyes
Daunorubicin was from Specia (Paris) and rhodamine 123
(Rhol23) was from Sigma (St Louis, MO, USA). 3,3'-
Diethyloxacarbocyanine iodide (DiOC2(3)) and the thiazole
orange derivatives SYTO13 [5 mm in dimethyl sulphoxide
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Figure 1 Time course of SYT016 accumulation in KB8 cells. Cells were incubated with 5 nm SYT016 with or without 2 gM PSC 833 and, after indicated time
points, the cells were washed and fluorescence was measured by flow cytometry. Data points are the mean of two determinations. A similar time curve was
obtained for the KB3-1 and KB8-5 cells
(DMSO)] and SYTO16 (1 mm in DMSO) were from Molecular
Probes (Eugene, OR, USA). Stock solutions of DNR (4 mm in
0.9% sodium chloride), Rhol23 (1 mg ml-1 in DMSO) and
DiOC2(3) (0.1 mm in DMSO) were stored at - 20°C. PSC 833 was
a gift from Sandoz (Basle, Switzerland) and was stored as 5 mm
stock solution in ethanol.
Dye accumulation
Cells were harvested and washed in accumulation medium
(DMEM without bicarbonate and phenol red but with 20 mM
Hepes and 10% FCS). About 0.5 x 106 cells were incubated in
eppendorf vials in 1 ml of accumulation medium with the dyes in
the indicated concentrations with or without the P-gp inhibitor
PSC 833 (2 gM). The vials were put in a 370C waterbath and care-
fully shaken. After the indicated time, the cells were immediately
centrifuged and washed with 1.5 ml ofcold accumulation medium,
resuspended in 1 ml ofmedium and kept on ice until analysis. The
cells were analysed by flow cytometry or by CLSM with image
analysis. In the latter case, the cells were centrifuged for 5 min at
350 r.p.m. on slides precoated with 0.1% bovine serum albumin
(about 35 000 KB cells per spin). Then the cells were fixed for
5 min with 3.6% formaldehyde solution, according to Willingham
et al (1986). After washing with tap water, the spins were air dried
horizontally in the dark and analysed immediately or stored in the
dark overnight before analysis. In preliminary experiments, the
results proved to be reproducible after storage for at least a week.
On one occasion, KB8 cells were grown on a round coverslip
(dimension 0 24 mm) for one night and were then layered
into accumulation medium in a temperature-controlled chamber
(37°C), allowing the recording of real-time fluorescence in the
cells during dye accumulation. For this experiment, cells were
exposed to 25 nm SYTO16 for 1 h, followed by 2 ,UM PSC 833.
After another hour, 3.6% formaldehyde solution was injected into
the chamber for fixation ofthe cells.
Flow cytometry
Fluorescence was analysed on a FACS Calibur (Becton Dickinson
Medical Systems, Sharon, MA, USA). The fluorescence of 10 000
events was logarithmically measured at a laser excitation of
488 nm. The fluorescence of Rhol23, DiOC2(3), SYTO13 and
SYTO16 was collected at 530 nm (band width 30 nm) and ofDNR
at 585 nm (band width 42 nm). P-gp status was assessed with the
monoclonal antibody MRK-16 (Dr T Tsuruo, Tokyo) and the
FITC-labelled second antibody exactly as described (Broxterman
et al, 1996b). The MRK-16 index is the ratio of the mean
fluorescence of MRK-16-labelled cells divided by that of the
isotype control antibody-labelled cells.
Fluorescence microscopy
An inverted confocal laser scanning microscope (CLSM) TCS 4D
(Leica, Heidelberg, Germany) equipped with an Ar/Kr laser and a
40 x /1.00-0.50 or 63 x /1.40 oil lens was used. Scanning, image
processing and microscope control were performed using an OS9
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Figure 2 Fluorescence in KB8 cells after incubation with 25 nm SYTO16. The cells were grown overnight on a coverslip and then put in a temperature-
controlled chamber for real-time fluorescence measurements. (A) Background. (B) Steady-state accumulation (45 min). (C) After addition of 2 gM PSC 833.
(D) 5 min after fixation with 3.6% formaldehyde
KB8 SYTO 16 + PSC 833
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Figure 3 Nuclear fluorescence per area of KB8 cells loaded for 45 min with
different concentrations of SYT016 with or without 2 1M PSC 833. After
loading, the cells were centrifuged and cytospins fixed with 3.6%
formaldehyde. The fluorescence values of about 200 nuclei per data point
were measured
minicomputer. Quantification of the images was performed with
Leica Q500MC QWin software. The fluorescence of about 200
nuclei on 3 or4 images from duplicate cytospins was recorded and
quantitated. After subtraction of the background (from the area
between the cells), the fluorescence of each nucleus was divided
by the nuclear area and reported as mean fluorescence per area of
about 200 cells.
RESULTS AND DISCUSSION
Tlhe novel nucleic acid (DNA and RNA)-binding dyes SYTO13
and SYTO16 were tested in an attempt to identify sensitive and
specific P-gp-activity probes applicable to flow cytometric as well
as CLSM analysis ofP-gp function. The SYTO dyes were chosen
Figure 4 Nuclear SYTO16 fluorescence in the absence (A, C and E) or
presence of PSC 833 (B, D and F) during dye loading in CD34+
haematopoietic cells (E and F) compared with KB3-1 (A and B) and KB8
(C and D) cells. Cells were cytocentrifuged after the appropriate labelling
and fixed with 3.6% formaldehyde
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because they exhibit a large increase in fluorescence upon nucleic
acid binding and because they can be excited at the convenient
wavelength of 488 nm. In addition, SYTO13 and SYTO16 have
one positive charge at physiological pH.
Flow cytometry
Cell lines
Inhibition of P-gp with 2 gM PSC 833 induced a large increase in
cellular SYTO13 and SYTO16 fluorescence in the P-gp-over-
expressing KB8-5 cells. No increase of fluorescence was seen
with the MRP inhibitor probenecid (1 mM; Feller et al, 1995a) in
the GLC4 and GLC4/ADR cells. In the MRP-overexpressing
HL60/ADR cells, we tested the two inhibitors probenecid and
genistein (200 gM) and, in addition, 2gM PSC 833, as this P-gp
inhibitor also inhibits MRP-mediated drug transport in
HL60/ADR but not in GLC4/ADR (Feller et al, 1995b). No effect
ofthese agents was seen in the HL60/ADR or the parental cell line
(Table 1). These data show the specificity of SYTO13 and
SYTO16 as substrates for P-gp.
More detailed investigations of the dyes were carried out using
the KB8 cells, which is the cell line with the lowest P-gp over-
expression available to us (Noonan et al, 1990). SYTO13 and
SYTO16 behaved in a very similar way. The time course of
SYTO16 accumulation in KB8 cells is shown in Figure 1. Steady-
state accumulation of both dyes was reached within 30 min, with
or without 2gM PSC 833. The 45-min accumulation ofboth dyes
was linear with the loading concentration being at least 1-25 nM
(data not shown).
Next, we compared the sensitivity of SYTO13 and SYTO16
with fluorescent dyes that are commonly used for flow cytometric
measurement of P-gp activity in leukaemias. Table 1 shows that
the increase of fluorescence of the SYTO dyes in KB8 cells after
P-gp inhibition with PSC 833 was of similar magnitude as that of
Rhol23 and DiOC2(3).
Cells from patients
As the ratio of active to passive drug transport, which largely
determines the net modulator effect, may be very different for
different cell types (and is actually low fordaunorubicin in the KB
cells; Spoelstra et al, 1992), we applied the present test to some
categories of cells for which it may be of value: normal human
(CD34+) cells, AML blasts and freshly dissociated solid tumour
(sarcoma) cells. Four AMLs were selected for P-gp expression
based on the MRK-16 labelling index - two with MRK-16 index
1.7, which is a value associated with low or absent functional P-gp
activity in AMLs as measured in a Rhol23 test (Broxterman et al,
1996b), and two AMLs with a high MRK-16 index (7.9 and 9.0). It
appeared that the modulation factor by PSC 833 in the P-gp+
human tumour samples and CD34+ cells was higher for SYTO16
than for Rhol23 (Table 1). One ofthe leiomyosarcomas (sarcoma
1), which had a very high P-gp expression as measured with MRK-
16 (see legend Table 1), also showed a large response to PSC 833,
in particular when SYTO16 was used as P-gp substrate. The
daunorubicin modulation ofthese cells was 2.7, which means that
after P-gp inhibition these cells take up almost three times more
daunorubicin. Such a large modulation has not been seen before,
by us, in AML cells (Broxterman et al, 1996b), and the modulation
was also much lower in the CD34+ cells. In addition, for this
sarcoma, the P-gp function was compared in fresh cells, cells that
had been stored overnight at 4°C and cells that were thawed after
freezing in liquid nitrogen. As shown in Table 1, there was excel-
lent agreement between the samples. A second leiomyosarcoma
(sarcoma 3) had a P-gp activity similar to that ofCD34+ cells, and
a liposarcoma (sarcoma 2) was P-gp negative. In conclusion, these
results show for the first time quantitative data on P-gp activity in
fresh human solid tumour cells and allow an estimation of the
impact ofP-gp on drug accumulation in these tumours.
Confocal laser scanning microscopy
Celllines
The flow cytometric method used to detect P-gp function estab-
lished SYTO16 as a sensitive P-gp activity probe for solid tumours
when ahigh yield ofviable single cells is available. CLSM may be
an alternative when only a small number of cells is available,
provided that the method is sensitive and reliable. Therefore, we
compared a CLSM method for the quantification of nuclear-fixed
SYTO16 with flow cytometric data. We have previously shown
that the low sensitivity ofdaunorubicin as a P-gp probe precluded
the accurate measurement of the PSC 833 effect in KB8 cells, as
well as in most AML samples, by CLSM analysis of about 200
cells (Broxterman et al, 1997). Using SYTO16 in KB8 cells, the
development offluorescence in individual cells was first followed
qualitatively in real time before and after the addition ofPSC 833
and after fixation. The increase in cellular SYTO16 fluorescence
upon addition of PSC 833 was clearly visible (Figure 2).
Moreover, after fixation, a large increase in nuclear fluorescence
occurred, while the cytoplasmic fluorescence largely disappeared.
To fully understand the biophysical nature of these changes, it
would be necessary to study further the chemical interaction of
SYTO16 with nucleic acids (DNA and RNA) under different
conditions. Here, we take advantage ofthe fact that fixation ofthe
dye allows a more practical assay. We found that the fluorescence
was linear, at least within the range ofconcentrations of SYTO16
that are convenient to use (5-25 nM) (see Figure 3). In practice, we
used a slightly higher concentration than for flow cytometry for
which 1-5 nm was satisfactory).
Cells frompatients
To demonstrate some potential applications, we analysed P-gp
function in CD34+ cells (an example is shown in Figure 4) and in
AML samples (see Table 1). The ratios of the nuclear SYTO16
fluorescence with or without PSC 833 were 4.0 for CD34+
samples, 0.8 and 1.1 for the Pgp- and 4.8 and 4.5 for the Pgp+
AMLs. This method was also applied to the sarcoma cells. For
example, in leiomyosarcoma 1, a PSC 833 effect on SYTO16
nuclear fluorescence of 10.7 was found by analysis of 204 cells
without (mean nuclear fluorescence 5.2 ± 3.3) and 218 cells with
PSC 833 (mean nuclear fluorescence 55.9 ± 16.3). The second
leiomyosarcoma had a PSC 833 effect of 3.9 and the liposarcoma
of 1.1 (Table 1). The results measured with the flow cytometer
correlated well withthe CLSM method. The CLSM method can be
used for combined staining of a plasma membrane antigen with
nuclear staining ofthe P-gp probe.
Cytotoxicity assay
We determined the cytotoxicity of SYTO16 in a clonogenic assay
for CD34+ cells from three individuals. No inhibition of clono-
genicity was found at concentrations of SYTO16 up to 10 nm.
Concentrations of 25 and 50 nM caused an inhibition of 20% and
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50% respectively. Thus, SYTO16 can be used at non-toxic concen-
trations for flow cytometric sorting of viable P-gp-expressing
CD34+ cells, similar to Rhol23 (Chaudhary and Roninson, 1991).
In summary, we have shown that SYTO16 is a highly sensitive
probe for P-gp activity in a number of different experimental set-
ups. In our present experiments, the sensitivity of the detection of
P-gp function was higher than for Rho123 in the tumour samples. It
is not clearwhy the difference in sensitivity between both probes for
different types of cells (e.g. compare AML4 and sarcoma 3) is not
the same, but factors related to passive membrane transport of the
probes might play a role. Another P-gp probe used previously by us
is calcein-AM (Feller et al, 1995b). As we found that the sensitivity
was no higher for calcein-AM than for Rhol23, we have not used it
in the present comparison. Probes other than Rhol23 may have
advantages in certain experimental situations (e.g. DiOC2(3); Leith
et al, 1995). It is important to realize that, for any new combination
of probe and modulator, one should be aware of putative interac-
tions with the fluorescence ofthe probe not related to pump activity
and appropriate controls have to be performed. We have discussed
the theoretical and practical considerations ofthe different probes in
a more comprehensive way in Broxterman et al (1997).
Of importance, the present data show that the membrane
integrity and the metabolic state of rapidly dissociated solid
tumour cells is apparently sufficient to study P-gp activity. From
previous experiments with human xenografts as a model
(Broxterman et al, 1995), these results were expected, but they
have now been shown for the first time in primary human tumour
cells. In particular, the large modulation of SYTO16 fluorescence
after P-gp inhibition, combined with the possibility to measure
nuclear-fixed dye at an excitation wavelength of 488 nm, allows
the reliable analysis ofarelatively small number oftumourcells by
CLSM. The concomitant analysis of P-gp activity and protein
expression with monoclonal antibodies in the same single cells is
possible. Clearly, the presupposition is that viable tumour cell
suspensions are available or can be prepared; in certain carcinomas
(breast), this may not be the case or more elaborate techniques may
have to be used (Ljung et al, 1989; Dairkee et al, 1995).
In conclusion, we propose that the methodology described here
to quantitate P-gp activity in normal as well as malignant blood
cell populations and in solid tumour cells is superior because ofits
combination of simplicity and sensitivity. It may be used in clin-
ical situations, such as the selection of patients for P-gp modula-
tion protocols.
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